Molecular radiobiology meets clinical radiation oncology

International Journal of Radiation Biology

Volumn 86, Issue 3, 2010, Pages 252-259

  Firat, Elke ^a   Heinemann, Felix ^a   Grosu, Anca Ligia ^a   Hermann, Frommhold ^a   Niedermann, Gabriele ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Clinical radiobiology; Molecular radiobiology; Radiotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; RADIOSENSITIZING AGENT;

ANGIOGENESIS; APOPTOSIS; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL DEATH; CELL HYPOXIA; CONFERENCE PAPER; DNA DAMAGE; IMMUNE SYSTEM; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIOBIOLOGY; RADIOSENSITIVITY; RISK FACTOR; STEM CELL; TISSUE INJURY; TREATMENT PLANNING;

DNA DAMAGE; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; RADIATION ONCOLOGY; RADIATION TOLERANCE; RADIOBIOLOGY; RADIOTHERAPY DOSAGE;

EID: 77749271116     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553000903419320     Document Type: Conference Paper

References (64)

1. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE. 2005. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clinical Cancer Research 11: 6270-6279.
2. Ashkenazi A. 2008. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nature Reviews Drug Discovery 7:1001-1012.
3. Baumann M, Krause M, Hill R. 2008. Clonogens and cancer stem cells. Nature Reviews Cancer 8:545-554.
4. Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, Picchio M, Souvatzoglou M, Machulla HJ, Piert M. 2007. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. Journal of Nuclear Medicine 48:973-980.
5. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M. 2007. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clinical Cancer Research 13:6610-6616.
6. Bentzen SM. 2006. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nature Reviews Cancer 6:702-713.
7. Bernier J, Bentzen SM, Vermorken JB. 2009. Molecular therapy in head and neck oncology. Nature Reviews Clinical Oncology 6: 266-277.
8. Bieler A, Mantwill K, Holzmuller R, Jurchott K, Kaszubiak A, Stark S, Glockzin G, Lage H, Grosu AL, Gansbacher B, Holm PS. 2008. Impact of radiation therapy on the oncolytic adenovirus d1520: Implications on the treatment of glioblastoma. Radiotherapy Oncology 86:419-427.
9. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. 2005. Opinion: Migrating cancer stem cells - an integrated concept of malignant tumour progression. Nature Reviews Cancer 5: 744-749.
10. Capalbo G, Rodel C, Stauber RH, Knauer SK, Bache M, Kappler M, Rodel F. 2007. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlentherapie und Onkologie 183:593-599.
11. Coppes RP, van der Goot A, Lombaert IM. 2009. Stem cell therapy to reduce radiation-induced normal tissue damage. Seminars in Radiation Oncology 19:112-121.
12. Cowen RL, Garside EJ, Fitzpatrick B, Papadopoulou MV, Williams KJ. 2008. Gene therapy approaches to enhance bioreductive drug treatment. The British Journal of Radiology 81(Spec. No. 1):S45-56.
13. Doil C, Mailand N, Bekker-Jensen S, Menard P, Larsen DH, Pepperkok R, Ellenberg J, Panier S, Durocher D, Bartek J, Lukas J, Lukas C. 2009. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 136:435-446.
14. Downs JA, Nussenzweig MC, Nussenzweig A. 2007. Chromatin dynamics and the preservation of genetic information. Nature 447:951-958.
15. Duda DG, Jain RK, Willett CG. 2007. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. Journal of Clinical Oncology 25:4033-4042.
16. Firat E, Tsurumi C, Gaedicke S, Huai J, Niedermann G. 2009. Tripeptidyl peptidase II plays a role in the radiation response of selected primary cell types but not based on nuclear translocation and p53 stabilization. Cancer Research 69:3325-3331.
17. Fodde R, Brabletz T. 2007. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Current Opinion in Cell Biology 19:150-158.
18. Formenti SC, Demaria S. 2008. Local control by radiotherapy: Is that all there is? Breast Cancer Research 10:215.
19. Frey B, Munoz LE, Pausch F, Sieber R, Franz S, Brachvogel B, Poschl E, Schneider H, Rodel F, Sauer R, Fietkau R, Herrmann M, Gaipl US. 2008. The immune reaction against allogeneic necrotic cells is reduced in AnnexinA5 knock out mice whose macrophages display an anti-inflammatory phenotype. Journal of Cellular and Molecular Medicine 13:1391-1399.
20. Gasser S, Raulet DH. 2006. The DNA damage response arouses the immune system. Cancer Research 66:3959-3962.
21. Gehrmann M, Radons J, Molls M, Multhoff G. 2008. The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. Cell Stress Chaperones 13:1-10.
22. Greubel C, Hable V, Drexler GA, Hauptner A, Dietzel S, Strickfaden H, Baur I, Krucken R, Cremer T, Dollinger G, Friedl AA. 2008. Competition effect in DNA damage response. Radiation and Environmental Biophysics 47: 423-429.
23. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, Wester HJ, Reischl G, Machulla HJ, Schwaiger M, Molls M, Piert M. 2007. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. International Journal Radiation Oncology Biology Physics 69:541-551.
24. Harper JW, Elledge SJ. 2007. The DNA damage response: Ten years after. Molecular Cell 28:739-745.
25. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM. 2008. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of chemotherapy and radiation therapy protectants. Journal of Clinical Oncology 27:127-145.
26. Hill RP, Marie-Egyptienne DT, Hedley DW. 2009. Cancer stem cells, hypoxia and metastasis. Seminars in Radiation Oncology 19:106-111.
27. Hsu PP, Sabatini DM. 2008. Cancer cell metabolism: Warburg and beyond. Cell 134:703-707.
28. Huai J, Firat E, Nil A, Million D, Gaedicke S, Kanzler B, Freudenberg M, van Endert P, Kohler G, Pahl HL, Aichele P, Eichmann K, Niedermann G. 2008. Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice. Proceedings of the National Academy of Sciences of the USA 105:5177-5182.
29. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE, Abdollahi A. 2005. Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Research 65: 3643-3655.
30. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. 2007. Angiogenesis in brain tumours. Nature Reviews Neuroscience 8:610-622.
31. Jung JW, Hwang SY, Hwang JS, Oh ES, Park S, Han IO. 2007. Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. European Journal of Cancer 43: 1214-1224.
32. Kepp O, Tesniere A, Zitvogel L, Kroemer G. 2009. The immunogenicity of tumor cell death. Current Opinion in Oncology 21:71-76.
33. Knopf A, Parodi K, Paganetti H, Cascio E, Bonab A, Bortfeld T. 2008. Quantitative assessment of the physical potential of proton beam range verification with PET/CT. Physics in Medicine and Biology 53:4137-4151.
34. Lobrich M, Jeggo PA. 2007. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nature Reviews Cancer 7:861-869.
35. Lombaert IM, Brunsting JF, Wierenga PK, Faber H, Stokman MA, Kok T, Visser WH, Kampinga HH, de Haan G, Coppes RP. 2008. Rescue of salivary gland function after stem cell transplantation in irradiated glands. PLoS ONE 3:e2063.
36. Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, Lukas J. 2007. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131:887-900.
37. Mansour WY, Schumacher S, Rosskopf R, Rhein T, Schmidt-Petersen F, Gatzemeier F, Haag F, Borgmann K, Willers H, Dahm-Daphi J. 2008. Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks. Nucleic Acids Research 36:4088-4098.
38. Marini P, Budach V, Niyazi M, Junginger D, Stickl S, Jendrossek V, Belka C. 2009. Combination of pro-apoptotic TRAIL-receptor antibodies with ionizing radiation strongly increases long term tumor control under ambient and hypoxic conditions. International Journal Radiation Oncology Biology Physics 75:198-202.
39. McKeown SR, Cowen RL, Williams KJ. 2007. Bioreductive drugs: From concept to clinic. Clinical Oncology 19:427-442.
40. Meyn RE, Milas L, Ang KK. 2009. The role of apoptosis in radiation oncology. International Journal of Radiation Biology 85:107-115.
41. Nieder C, Wiedenmann N, Andratschke N, Molls M. 2006. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treatment Reviews 32:348-364.
42. Niyazi M, Marini P, Daniel PT, Humphreys RH, Jendrossek V, Belka C. 2009. Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade. Strahlentherapie und Onkologie 185:8-18.
43. Oehler-Janne C, Jochum W, Riesterer O, Broggini-Tenzer A, Caravatti G, Vuong V, Pruschy M. 2007. Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models. Molecular Cancer Therapeutics 6:2496-2504.
44. Orlowski RZ, Kuhn DJ. 2008. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clinical Cancer Research 14:1649-1657.
45. Pan JG, Mak TW. 2007. Metabolic targeting as an anticancer strategy: Dawn of a new era? Science's Signal Transduction Knowledge Environment 2007: pe14.
46. Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, Mueller-Klieser W. 2006. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiotherapy Oncology 81:130-135.
47. Rich JN. 2007. Cancer stem cells in radiation resistance. Cancer Research 67:8980-8984.
48. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S, Pruschy M. 2006. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clinical Cancer Research 12:3518-3524.
49. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ. 2006. Prognostic significance of [18F]-misonidazole positron emission tomographydetected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. Journal of Clinical Oncology 24:2098-2104.
50. Rodemann HP, Dittmann K, Toulany M. 2007. Radiation-induced EGFR-signaling and control of DNA-damage repair. International Journal Radiation Biology 83:781-791.
51. Rosenthal DI, Trotti A. 2009. Strategies for managing radiation-induced mucositis in head and neck cancer. Seminars in Radiation Oncology 19:29-34.
52. Schutze C, Bergmann R, Yaromina A, Hessel F, Kotzerke J, Steinbach J, Baumann M, Beuthien-Baumann B. 2007. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiotherapy Oncology 83:311-315.
53. Unkelbach J, Chan TC, Bortfeld T. 2007. Accounting for range uncertainties in the optimization of intensity modulated proton therapy. Physics in Medicine and Biology 52:2755-2773.
54. Wiegman EM, Blaese MA, Loeffler H, Coppes RP, Rodemann HP. 2007. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiotherapy Oncology 83:289-295.
55. Willers H, Dahm-Daphi J, Powell SN. 2004. Repair of radiation damage to DNA. British Journal of Cancer 90:1297-1301.
56. Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK. 2007. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nature Clinical Practice Oncology 4:316-321.
57. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563.
58. Woodward WA, Bristow RG. 2009. Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Seminars in Radiation Oncology 19:87-95.
59. Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. 2009. Radiation Therapy Oncology Group Translational Research Program Stem Cell Symposium: Incorporating stem cell hypotheses into clinical trials. International Journal Radiation Oncology Biology Physics 74: 1580-1591.
60. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. 2007. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proceedings of the National Academy of Sciences of the USA 104:618-623.
61. Yaromina A, Krause M, Thames H, Rosner A, Krause M, Hessel F, Grenman R, Zips D, Baumann M. 2007. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiotherapy Oncology 83:304-310.
62. Yaromina A, Zips D, Thames HD, Eicheler W, Krause M, Rosner A, Haase M, Petersen C, Raleigh JA, Quennet V, Walenta S, Mueller-Klieser W, Baumann M. 2006. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. Radiotherapy Oncology 81:122-129.
63. Zhang P, Castedo M, Tao Y, Violot D, Metivier D, Deutsch E, Kroemer G, Bourhis J. 2006. Caspase independence of radio-induced cell death. Oncogene 25:7758-7770.
64. Zips D, Krause M, Yaromina A, Dorfler A, Eicheler W, Schutze C, Gurtner K, Baumann M. 2008. Epidermal growth factor receptor inhibitors for radiotherapy: Biological rationale and preclinical results. Journal of Pharmacy and Pharmacology 60:1019-1028.